Analysis of the cellular centrosome in fine-needle aspirations of the breast.
Analysis of the cellular centrosome in fine-needle aspirations of the breast.
复制标题
DOI：
10.1186/bcr1752
复制
发表时间：
2007
期刊：
影响因子：
--
通讯作者：
Pan QJ
中科院分区：
文献类型：
--
作者：
Guo HQ;Gao M;Ma J;Xiao T;Zhao LL;Gao Y;Pan QJ
本研究旨在探讨乳腺肿瘤细胞中是否存在中心体扩增，乳腺良性病变与乳腺癌之间是否存在中心体扩增的差异，以及中心体分析对乳腺癌的诊断和预后判断是否有价值。我们使用抗γ-微管蛋白抗体的免疫荧光分析，分析了100例乳腺病变（25例良性病变和75例癌）细针穿刺的中心体异常。我们发现，中心体扩增，包括数字中心体扩增和结构中心体扩增，存在于大多数乳腺肿瘤。25例乳腺良性病变中23例出现中心体扩增，75例乳腺癌均出现中心体扩增。结构中心体扩增的细胞在25例良性病变中有3例，在75例乳腺癌中有69例。乳腺癌中中心体数目扩增的细胞百分比平均为4.86%，中心体结构扩增的细胞百分比平均为3.98%。这些百分比明显高于良性病变，其中数值中心体扩增为2.77%，结构中心体扩增为0.10%。此外，乳腺癌中结构中心体扩增细胞的平均百分比与HER 2/neu过表达（P < 0.05）和雌激素受体阴性状态（P < 0.05）显著相关，与孕激素受体阴性状态（P = 0.056）存在临界相关性。结构中心体扩增可能与乳腺癌的发生密切相关，并可能成为乳腺癌诊断和预后的潜在生物标志物。
The purpose of the present investigation is to determine whether centrosome amplifications are present in breast tumor cells, whether there are differences of centrosome amplification between benign breast lesions and breast carcinomas, and whether centrosomal analysis can be of value in the diagnosis and prognosis of breast carcinoma. Using immunofluorescence analysis with an antibody against γ-tubulin, we analyzed centrosome abnormalities in fine-needle aspirations of 100 breast lesions (25 cases with benign lesions and 75 cases with carcinomas). We found that centrosome amplifications, including numerical centrosome amplification and structural centrosome amplification, were present in most breast tumors. Cells with numerical centrosome amplification were found in 23 of 25 benign lesions, and in all 75 cases of breast carcinomas. Cells with structural centrosome amplification were found in three of 25 benign lesions, and in 69 of 75 breast carcinomas. The breast carcinomas showed a mean percentage of cells with numerical centrosome amplification of 4.86% and a mean percentage of cells with structural centrosome amplification of 3.98%. These percentages were significantly higher than those in benign lesions, with a numerical centrosome amplification of 2.77% and a structural centrosome amplification of 0.10%. Furthermore, the mean percentage of cells with structural centrosome amplification was significantly associated with HER2/neu overexpression (P < 0.05) and with negative estrogen receptor status (P < 0.05), and had a borderline association with negative progesterone receptor status (P = 0.056) in breast carcinomas. Structural centrosome amplification may bear a close relationship with breast carcinoma and may be a potential biomarker for diagnosis and prognosis of breast carcinoma.